Pieter Rottiers, CEO of ActoBio Therapeutics
Pieter is CEO of ActoBio Therapeutics™, a clinical-stage biopharmaceutical company developing ActoBiotics®, a new localized therapeutics platform with potential disease-modifying capabilities in auto-immune and allergic diseases.
The recent SynBioBeta engineered cell therapy digest featured Pieter discussing living medicines and the ActoBiotics® approach, focusing on AG019, their potential cure for early-onset type 1 diabetes, which is currently in a phase Ib/IIa clinical trial.
Since the 2006 founding of the company’s previous incarnation, ActoGenix, Pieter has been involved in the development of the safe, effective technology which is based on genetically engineered Lactococcus lactis.
Prior to the formation of ActoGenix, Pieter earned his PhD in Biotechnology from the University of Ghent, Belgium, where he later became Principal Investigator researching the therapeutic potential of engineered L. lactis.